Announcements
Excerpt from the Press Release: CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial. This is a first-in-human, multi-center, open label study designed to evaluate the…
Read More
Maze Therapeutics Announces Initiation of Dosing in Phase 1 Trial Evaluating MZE829, a Novel Oral APOL1 Inhibitor, as a Potential Treatment for APOL1 Kidney Disease Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the initiation of dosing in the company’s Phase…
Read More
Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation (“Immusoft”), a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced the first patient dosed with engineered B cell therapy ISP-001 in a Phase 1 trial in MPS I, at M…
Read More
Excerpt from the Press Release: LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), announced the design of the Phase II trial of alisertib for the treatment of patients with HER2-negative, hormone receptor-positive metastatic breast cancer (PUMA-ALI-1201). Based on the Company’s interactions with the U.S. Food and Drug Administration (FDA), the Company…
Read More
DARE-PTB1 is being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment options Up to approximately $2 million in grant funding to support DARE-PTB1 Phase 1 human clinical study Excerpt from the Press Release: SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) — DARÉ Bioscience, Inc. (NASDAQ: DARE),…
Read More
Tumor Regression and Improved Patient Performance are Among the Early Findings Excerpt from the Press Release: OAKLAND, Calif.–(BUSINESS WIRE)–SonALAsense, a pioneer in the development of non-invasive Sonodynamic Therapy (SDT) using SONALA-001 (aminolevulinic acid HCl) in combination with Insightec’s Exablate 4000 Type-2 ultrasound device today announced the presentation of positive preliminary data from the ongoing Phase…
Read More
Plans to report topline data mid-second quarter 2024 Excerpt from the Press Release: REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the completion of enrollment in its RZ402 Phase 2 study in diabetic macular…
Read More
— Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT — — ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2 2024 — — Caribou plans to initiate Phase…
Read More
Excerpt from the Press Release: Although a 1972 United Nations (UN) resolution prohibits member states from using biological weapons on military personnel and civilians (1, 2), a lack of robust verification protocols has enabled several countries to develop such agents (3). Several groups that the UN considers to be global terrorist organizations also are establishing…
Read More
Excerpt from the Press Release: While a recent report issued by the Centers for Disease Control and Prevention (CDC) noted that 30 percent of children with autism were not diagnosed at eight years of age, emerging research suggests that a combination of artificial intelligence (AI) and diffusion tensor magnetic resonance imaging (DT-MRI) facilitates autism detection…
Read More